A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Phase 1 Part (Complete): Open-label, sequential dose escalation study of CPI-0610 in patients
with previously treated Acute Leukemia, Myelodysplastic Syndrome,
Myelodysplastic/Myeloproliferative Neoplasms, and Myelofibrosis.
Phase 2 Part: Open-label study of CPI-0610 with and without Ruxolitinib in patients with
Myelofibrosis.
CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.